The antiepileptic drug levetiracetam improves auditory gating in DBA/2 mice

npj Schizophrenia

Volumn 1, Issue 1, 2015, Pages

  Smucny, Jason ^a,b,c   Stevens, Karen E ^c   Tregellas, Jason R ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVETIRACETAM;

ANIMAL EXPERIMENT; ARTICLE; AUDITORY EVOKED POTENTIAL; AUDITORY STIMULATION; DBA 2 MOUSE; DRUG DOSE INCREASE; DRUG EFFECT; HIPPOCAMPUS; IN VIVO STUDY; LOW DRUG DOSE; MALE; MOUSE; NEUROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING; WAVEFORM;

EID: 84958130075     PISSN: None     EISSN: 2334265X     Source Type: Journal    
DOI: 10.1038/npjschz.2015.2     Document Type: Article

References (24)

1. Potter D, Summerfelt A, Gold J, Buchanan RW. Review of clinical correlates of P50 sensory gating abnormalities in patients with schizophrenia. Schizophr Bull 2006; 32: 692-700.
2. Smucny J, Olincy A, Eichman LC, Lyons E, Tregellas JR. Early sensory processing deficits predict sensitivity to distraction in schizophrenia. Schizophr Res 2013; 147: 196-200.
3. Venables P. Input dysfunction in schizophrenia. Maher BA (ed). Progress in Experimental Personality Research. Academic Press: Orlando, FL, USA: 1967.
4. Kornetsky C, Mirsky AF. On certain psychopharmacological and physiological differences between schizophrenic and normal persons. Psychopharmacologia 1966; 8: 309-318.
5. Burwell RD. The parahippocampal region: corticocortical connectivity. Ann N Y Acad Sci 2000; 911: 25-42.
6. Bak N, Rostrup E, Larsson HB, Glenthoj BY, Oranje B. Concurrent functional magnetic resonance imaging and electroencephalography assessment of sensory gating in schizophrenia. Hum Brain Mapp 2014; 35: 3578-3587.
7. Olincy A, Stevens KE. Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men. Biochem Pharmacol 2007; 74: 1192-1201.
8. Bakker A, Krauss GL, Albert MS, Speck CL, Jones LR, Stark CE et al. Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 2012; 74: 467-474.
9. Sanchez PE, Zhu L, Verret L, Vossel KA, Orr AG, Cirrito JR et al. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA 2012; 109: E2895-E2903.
10. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85.
11. Tregellas JR, Smucny J, Harris JG, Olincy A, Maharajh K, Kronberg E et al. Intrinsic Hippocampal Activity as a Biomarker for Cognition and Symptoms in Schizophrenia. Am J Psychiatry 2014; 171: 549-556.
12. Tregellas JR. Neuroimaging biomarkers for early drug development in schizophrenia. Biol Psychiatry 2014; 76: 111-119.
13. Tamminga CA, Stan AD, Wagner AD. The hippocampal formation in schizophrenia. Am J Psychiatry 2010; 167: 1178-1193.
14. Das T, Ivleva EI, Wagner AD, Stark CE, Tamminga CA. Loss of pattern separation performance in schizophrenia suggests dentate gyrus dysfunction. Schizophr Res 2014; 159: 193-197.
15. Smucny J, Stevens KE, Tregellas JR. Acute administration of Delta(9) tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice. Pharmacol Biochem Behav 2014; 118: 22-29.
16. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661.
17. Deshpande LS, Delorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol 2014; 5: 11.
18. Lewis DA, Curley AA, Glausier JR, Volk DW. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012; 35: 57-67.
19. Wildeboer-Andrud KM, Zheng L, Choo KS, Stevens KE. Cotinine impacts sensory processing in DBA/2 mice through changes in the conditioning amplitude. Pharmacol Biochem Behav 2014; 117: 144-150.
20. Stevens KE, Wear KD. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 1997; 57: 869-874.
21. Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K et al. Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 1998; 24: 189-202.
22. Stevens KE, Kem WR, Mahnir VM, Freedman R. Selective alpha7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology (Berl) 1998; 136: 320-327.
23. O'Neill HC, Rieger K, Kem WR, Stevens KE. DMXB, an alpha7 nicotinic agonist, normalizes auditory gating in isolation-reared rats. Psychopharmacology (Berl) 2003; 169: 332-339.
24. Kalviainen R. Long-Term safety of tiagabine. Epilepsia 2001; 42: 46-48.